荣昌生物：RC148获CDE突破性治疗药物认定

Core Viewpoint - Rongchang Biopharma's innovative bispecific antibody RC148 has been officially included by the China National Medical Products Administration (NMPA) as a breakthrough therapy for specific indications in non-small cell lung cancer (NSCLC) [1] Group 1 - The indication for RC148 is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed PD-1/PD-L1 inhibitors and platinum-based chemotherapy [1] - RC148 is to be used in combination with docetaxel for the specified patient population [1]